摘要
目的 探讨LRIG1在前列腺癌和前列腺增生组织中的表达及临床意义.方法 采用免疫组织化学SP法检测LRIG1蛋白在23例前列腺癌和26例前列腺增生组织中的表达情况,并结合临床进行分析.结果 LRIG1蛋白在前列腺癌组织中和前列腺增生组织中阳性表达率分别为13.04%（3/23）和96.15%（25/26）,差异有统计学意义（P〈0.05）.结论 与前列腺增生组织相比,LRIG1在前列腺癌中表达水平较低,该基因的表达可作为前列腺癌诊断的参考指标.
Objective To investigate the clinical significance of LRIG1 expressions in prostatic carcinoma tissues and benign prostatic hyperplasia tissues. Methods Expressions of LRIG1 in 23 prostatic carcinoma tissues and 26 BPH tissues were detected respectively by immunohistochemistry. Patterns of LRIG1 expression were analyzed in combining with clinical data of patients. Results The positive rates of LRIG1 in prostatic carcinoma tissues and BPH tissues were 13.04% （3/23） and 96.15%（25/26） respectively, significantly（P〈0.05）. Conclusion Compared with that in BPH tissues, LRIG1 expression significantly decreased in prostate carcinoma tissues. LRIG1 might be an index for diagnosis of prostatic carcinoma.
出处
《中国男科学杂志》
CAS
CSCD
2011年第1期8-10,共3页
Chinese Journal of Andrology
基金
卢湾区卫生局立项课题 （编号：卢卫科08008）
